Drug Trial News

RSS

Mast Therapeutics' data show that MST-188 reduces aggregation of both older and younger RBC

Mast Therapeutics, Inc. today announced that two posters for its lead product candidate, MST-188, were presented at the 7th Annual Sickle Cell Disease Research & Educational Symposium, currently underway in Miami.

18 Apr 2013

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Scientists from academic institutions reported at the 2013 annual American Association for Cancer Research meeting, results from preclinical studies which showed that certain bladder cancers and mesotheliomas have metabolic changes and are more likely to respond to treatment with ADI-PEG 20 (pegylated arginine deiminase) if they are deficient in the enzyme, argininosuccinate synthetase.

18 Apr 2013

Phase III clinical trial data of Milprosa vaginal ring presented at PCRS annual meeting

Teva Pharmaceutical Industries Ltd. today presented data from a sub-analysis of a Phase III clinical trial of Milprosa (progesterone) vaginal ring, an investigational, once-weekly therapy for luteal phase support in women undergoing in vitro fertilization.

18 Apr 2013

New pre-clinical study suggests novel drug combination therapy for leukemia treatment

A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins.

18 Apr 2013

IDRI, Medicago announce positive Phase I clinical trial results for avian flu pandemic vaccine

IDRI, a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a Phase I clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.

18 Apr 2013

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

Patients with a type of cancer known as primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to an area of the thorax known as the mediastinum, had excellent outcomes, according to clinical trial results.

18 Apr 2013

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

RNAi-based therapeutics company Benitec Biopharma Limited today announced that the company's wholly owned US subsidiary, Tacere Therapeutics Inc., has submitted an application to the US National Institutes of Health's Recombinant DNA Advisory Committee.

18 Apr 2013

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

BioLineRx, a biopharmaceutical development company, announced today positive Phase IIa results for BL-7040, an orally available drug for treating inflammatory bowel disease.

17 Apr 2013

Flunisyn Phase 2a trial data shows positive results in elderly population

Following the widely publicised US Centers for Disease Control and Prevention report in February that the current season's flu vaccine is only 9% effective in the over-65 population, Immune Targeting Systems Limited, today announces positive data from a Phase 2a trial with the Company's lead pan-strain influenza A T-cell vaccine, Flunisyn, in the elderly population.

17 Apr 2013

GlycoMimetics reports Phase 2 clinical study results of GMI-1070

GlycoMimetics, Inc. today announced top line clinical results from a Phase 2 study of GMI-1070 in patients experiencing vaso-occlusive crisis of sickle cell disease.

17 Apr 2013

Preclinical data on anti-cancer activity of BI-505 published online in Cancer Cell

BioInvent International AB, a biotech company developing novel antibody therapeutics for treatment of cancer, today announced that the April 15, 2013 online issue of the highly prestigious cancer research journal Cancer Cell features a data publication demonstrating potent anti-cancer activity of BI-505 in multiple preclinical myeloma tumor models.

17 Apr 2013

COPD phase III study by Almirall and Forest Laboratories announces positive results

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered by Almirall’s inhaler Genuair® (Pressair™ in the USA).

16 Apr 2013

Rhythm starts RM-131 Phase 2 clinical trial for treatment of chronic constipation

Rhythm announced today the initiation of an additional Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the treatment of chronic constipation. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal motility.

16 Apr 2013

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

RNAi-based therapeutics company Benitec Biopharma Limited today announced the selection of the University of California, San Diego, Health Sciences as the second site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C infections.

16 Apr 2013

Study on targeted liver cancer therapy called SIR-Spheres microspheres completes patient recruitment

Australian-based global oncology company, Sirtex Medical Limited (ASX: SRX), has announced the completion of patient recruitment for its global SIRFLOX clinical study which is aimed at expanding the clinical use of its SIR-spheres® microspheres targeted radiation therapy from a last line medical treatment to a standard first-line oncology therapy.

16 Apr 2013

GTx to continue two pivotal Phase III clinical trials of enobosarm

GTx, Inc. today announced that a per protocol safety review of unblinded safety data on Friday April 12, 2013, by an independent Data Safety Monitoring Board, resulted in a determination that GTx continue as planned its two pivotal Phase III clinical trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer.

16 Apr 2013

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Acorda Therapeutics, Inc. today announced that a proof-of-concept trial found dalfampridine extended release tablets, marketed as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.

16 Apr 2013

NeuroDerm enrolls patients for Phase IIa clinical trial of ND0612

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.

16 Apr 2013

L-carnitine improves cardiac health in patients after heart attack, say researchers

L-carnitine significantly improves cardiac health in patients after a heart attack, say a multicenter team of investigators in a study published today in Mayo Clinic Proceedings.

15 Apr 2013

KYTHERA Biopharmaceuticals reports positive results from Phase IIb study of ATX-101

KYTHERA Biopharmaceuticals, Inc. today presented positive results that found MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat, commonly known as double chin, during an oral session at The Aesthetic Meeting 2013, organized by the American Society for Aesthetic Plastic Surgery, April 11-16, New York, NY.

15 Apr 2013

Drug Trial News

Mast Therapeutics' data show that MST-188 reduces aggregation of both older and younger RBC

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Phase III clinical trial data of Milprosa vaginal ring presented at PCRS annual meeting

New pre-clinical study suggests novel drug combination therapy for leukemia treatment

IDRI, Medicago announce positive Phase I clinical trial results for avian flu pandemic vaccine

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

Flunisyn Phase 2a trial data shows positive results in elderly population

GlycoMimetics reports Phase 2 clinical study results of GMI-1070

Preclinical data on anti-cancer activity of BI-505 published online in Cancer Cell

COPD phase III study by Almirall and Forest Laboratories announces positive results

Rhythm starts RM-131 Phase 2 clinical trial for treatment of chronic constipation

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

Study on targeted liver cancer therapy called SIR-Spheres microspheres completes patient recruitment

GTx to continue two pivotal Phase III clinical trials of enobosarm

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

NeuroDerm enrolls patients for Phase IIa clinical trial of ND0612

L-carnitine improves cardiac health in patients after heart attack, say researchers

KYTHERA Biopharmaceuticals reports positive results from Phase IIb study of ATX-101

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News